Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18156174 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kang S, et al. (2008) Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. J Biol Chem 283, 4652-7 18156174
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S386-p - RSK2 (human) ▲
Orthologous residues
RSK2 (human): S386‑p, RSK2 (mouse): S386‑p, RSK2 (rat): S386‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
PP2 EGF inhibit treatment-induced increase

Y470-p - RSK2 (human) ▲
Orthologous residues
RSK2 (human): Y470‑p, RSK2 (mouse): Y470‑p, RSK2 (rat): Y470‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Fyn (human)
KINASE Src (human)

Y483-p - RSK2 (human) ▲
Orthologous residues
RSK2 (human): Y483‑p, RSK2 (mouse): Y483‑p, RSK2 (rat): Y483‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Fyn (human)
KINASE Src (human)

Y488-p - RSK2 (human) ▲
Orthologous residues
RSK2 (human): Y488‑p, RSK2 (mouse): Y488‑p, RSK2 (rat): Y488‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Src (human)
KINASE Fyn (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) phospho-motif antibody, transfection of constitutively active enzyme, modification site within consensus motif

Y529-p - RSK2 (human) ▲
Orthologous residues
RSK2 (human): Y529‑p, RSK2 (mouse): Y529‑p, RSK2 (rat): Y529‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Fyn (human)
KINASE FGFR3 (human)
KINASE Src (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
KINASE Fyn (human) pharmacological inhibitor of upstream enzyme, phospho-antibody, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF no effect upon treatment-induced increase
PP2 EGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
ERK2 (human) Induces co-immunoprecipitation
ERK1 (human) Induces co-immunoprecipitation

Y580-p - RSK2 (human) ▲
Orthologous residues
RSK2 (human): Y580‑p, RSK2 (mouse): Y580‑p, RSK2 (rat): Y580‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Src (human)
KINASE Fyn (human)

Y644-p - RSK2 (human) ▲
Orthologous residues
RSK2 (human): Y644‑p, RSK2 (mouse): Y644‑p, RSK2 (rat): Y644‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Fyn (human)
KINASE Src (human)

Y707-p - RSK2 (human) ▲
Orthologous residues
RSK2 (human): Y707‑p, RSK2 (mouse): Y707‑p, RSK2 (rat): Y707‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Src (human)
KINASE Fyn (human)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.